As the buzz increases in volume and the clock to kick-off counts down, keep an eye on this Spotlight On page for content ...

New hope is on the horizon in the fight against cancer. At this year’s American Society of Clinical Oncology (ASCO) annual ...

When an RSV vaccine became available for use during pregnancy, it offered a natural experiment between various countries to ...

Drugmakers unveil cancer drug data at the ASCO annual meeting, while Amazon Pharmacy announces new features for caregivers, ...

Neoadjuvant nivolumab (Opdivo) plus chemotherapy significantly improved overall survival (OS) compared with chemotherapy ...

AstraZeneca's camizestrant and Pfizer's vepdegestrant extended progression-free survival in trials in advanced ESR1-mutated breast cancer.

Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding ...

The large molecule injectable drugs market is anticipated to expand at a CAGR of ~9% during the forecast period. Key drivers ...

A colon cancer study highlighted the importance of the National Cancer Institute, while cancer doctors got a look at a ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...